Zusammenfassung
Unter Basistherapeutika (DMARDs, „disease modifying antirheumatic drugs“) versteht man Medikamente, die bei der rheumatoiden Arthritis (RA) entzündungshemmend und schmerzlindernd wirken, die Gelenkzerstörung vermindern und die Langzeitprognose verbessern. Von Glukokortikoiden sind seit langem ihre immunmodulatorischen, antiphlogistischen und schmerzlindernden Wirkungen bekannt. Darüber hinaus wurde in einigen Studien und nun auch in einer systematischen Analyse diesbezüglicher Studienergebnisse gezeigt, dass sie zur Verminderung der radiographischen Progredienz dieser Erkrankung beitragen. Aus diesen Gründen können Glukokortikoide als Basistherapeutika angesehen werden, wenn sie – so die derzeitige Studienlage – bei der frühen RA in Kombination mit anderen DMARDs eingesetzt werden.
Abstract
Drugs used for managing rheumatoid arthritis (RA) are designated disease-modifying antirheumatic drugs (DMARDs) if they reduce inflammation and pain, limit joint destruction, and improve long-term disease outcome. Glucocorticoids have long been known to have anti-inflammatory, immunosuppressive, and pain-reducing effects. Moreover, they have been shown in recent clinical trials, and also very recently in a systemic analysis of the results of these studies, to contribute to inhibition of the radiographic progression of RA. For these reasons, glucocorticoids can be considered DMARDs if they are used to treat patients suffering from early RA and, according to the current knowledge, are used in combination with other DMARDs.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Buttgereit F, Straub RH, Wehling M, Burmester GR (2004) Glucocorticoids in the treatment of rheumatic diseases. An update on mechanisms of action. Arthritis Rheum 50: 3408–3417
Bijlsma JWJ, Hoes JN, van Everdingen AA (2006) Are Glucocorticoids DMARDs? Ann N Y Acad Sci 1069: 268–274
Bijlsma JWF, Buttgereit F, Jacobs JWG (2006) Systemic and intra-articular glucocorticoids in rheumatoid arthritis. In: Firestein GS, Panayi GS, Wollheim FA (eds) Rheumatoid Arthritis. Oxford University Press, pp 337–354
Buttgereit F, Saag K, Cutolo M et al. (2005) The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheum 34:14–21
Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136: 1–12
Jacobs JW, van Everdingen AA, Verstappen SMM, Bijlsma JW (2006) Follow-up radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 54: 1422–1428
Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333: 142–146
Boers M, Verhoeven AC, Markusse HM et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350: 309–318
Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double blind placebo-controlled trial. Arthritis Rheum 52: 3371–3380
Svensson B, Boonen A, Albertsson K et al. (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52: 3360–3370
Capell HA, Madhok R, Hunter JA et al. (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63: 797–803
Kirwan JBijlsma JWJ, Boers M, Shea B (2007) Effects of glucocorticoids on radiological progession in rheumatoid arthritis. Cochrane Databas Syst Rev Jan 24;1:CD006356
Interessenkonflikt
Frank Buttgereit, Gerd-Rüdiger Burmester und Johannes Bijlsma haben Referenten- und/oder Konsultationshonorare und/oder Forschungsgelder erhalten von: Abbott GmbH & Co. KG, Medac GmbH, Merck Pharma GmbH, Nitec Pharma GmbH, Organon, Pfizer GmbH, Roche, Wyeth GmbH. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Buttgereit, F., Burmester, G., Bijlsma, J. et al. Krankheitsmodifizierende Effekte bei der rheumatoiden Arthritis durch Glukokortikoide. Z. Rheumatol. 66, 522–524 (2007). https://doi.org/10.1007/s00393-007-0185-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-007-0185-1